Moderna Stock Plunges 12% As Q3 Results Miss Estimates

moderna covid19 vaccine 113020 03nov22 lt

Biotechnology company Moderna, Inc. (MRNA) reported a profit for the third quarter that plunged 69 percent from last year, reflecting a drop in COVID-19 vaccines sales and higher operating expenses. Both earnings per share and revenues for the quarter missed analysts' expectations.

In pre-market activity on Nasdaq, Moderna shares are plunging $18.52 or 12.46 percent to trade at $130.10.

For the third quarter, the company reported net income of $1.04 billion or $2.53 per share, down from $3.33 billion or $7.70 per share in the prior-year quarter.

On average, 13 analysts polled by Thomson Reuters expected the company to report earnings of $3.29 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter declined to $3.36 billion from last year's $4.97 billion, resulting mainly due to a decline in sales of the company's COVID-19 vaccines. Analysts expected revenues of $3.53 billion for the quarter.

Product sales for the quarter decreased 35 percent to $3.1 billion from last year, primarily driven by lower sales volume due to the timing of market authorizations for our COVID-19 bivalent boosters and the related manufacturing ramp up.

Total operating expenses surged to $2.20 billion from $1.41 billion last year, primarily hurt by a charge of $333 million for inventory write-downs related to COVID-19 products, increased clinical trial-related expenses and increased headcount.

Moderna said it now has 48 programs in development across 45 development candidates, of which 35 are currently in active clinical trials.

Looking ahead, the company has already signed advance purchase agreements or APAs for product sales of approximately $18 billion to 19 billion for anticipated deliveries in 2022 following delay of $2 billion to $3 billion for deliveries into 2023, due to short-term supply constraints.

The confirmed APAs, as well as previously deferred product sales, currently represent $4.5 billion to $5.5 billion in anticipated product sales in 2023. The Company expects additional sales in key markets, including the U.S., E.U., Japan, Middle East, Latin America and Asia Pacific in 2023.

"With $13.6 billion in product sales through the first three quarters of the year, and advance purchase agreements for anticipated delivery this year now expected to produce around $18 to $19 billion of product sales, we continue to have a strong financial position as we prepare for multiple upcoming global product launches," said Stéphane Bancel, Chief Executive Officer of Moderna.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT